Inflarx NV (NASDAQ:IFRX) Sees Significant Growth in Short Interest

Inflarx NV (NASDAQ:IFRX) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 1,242,600 shares, an increase of 32.0% from the May 30th total of 941,700 shares. Approximately 8.2% of the shares of the stock are short sold. Based on an average daily volume of 1,560,000 shares, the short-interest ratio is presently 0.8 days.

Several research analysts have commented on IFRX shares. ValuEngine downgraded shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Raymond James reissued a “buy” rating on shares of Precision Drilling in a report on Wednesday, June 5th. Leerink Swann downgraded shares of Inflarx from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 5th. Guggenheim downgraded shares of Inflarx from a “buy” rating to a “neutral” rating and cut their price target for the company from $65.00 to $6.00 in a report on Wednesday, June 5th. Finally, SunTrust Banks downgraded shares of Inflarx from a “buy” rating to a “hold” rating and cut their price target for the company from $55.00 to $5.00 in a report on Wednesday, June 5th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $15.72.

NASDAQ:IFRX traded down $0.04 during trading hours on Friday, hitting $3.24. The stock had a trading volume of 733,035 shares, compared to its average volume of 1,270,417. The business’s 50 day moving average price is $11.08. Inflarx has a one year low of $2.91 and a one year high of $53.10. The stock has a market cap of $85.16 million, a price-to-earnings ratio of -2.31 and a beta of -1.52.



Inflarx (NASDAQ:IFRX) last announced its quarterly earnings results on Thursday, May 23rd. The company reported ($0.43) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.19. On average, analysts anticipate that Inflarx will post -2.09 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Redmile Group LLC lifted its holdings in shares of Inflarx by 7.2% during the 1st quarter. Redmile Group LLC now owns 2,182,638 shares of the company’s stock worth $82,482,000 after acquiring an additional 147,238 shares during the last quarter. RA Capital Management LLC lifted its holdings in shares of Inflarx by 6.0% during the 4th quarter. RA Capital Management LLC now owns 2,085,089 shares of the company’s stock worth $75,835,000 after acquiring an additional 117,241 shares during the last quarter. FMR LLC bought a new stake in shares of Inflarx during the 1st quarter worth $9,609,000. Polar Capital LLP lifted its holdings in shares of Inflarx by 54.4% during the 4th quarter. Polar Capital LLP now owns 141,887 shares of the company’s stock worth $5,160,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new stake in shares of Inflarx during the 1st quarter worth $3,094,000. 55.89% of the stock is owned by institutional investors.

Inflarx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

Further Reading: The primary rules of Elliott Wave theory

Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.